The MOBILE study, sponsored by DexCom, Inc., aims to evaluate the efficacy of the Dexcom G6 CGM system compared to traditional self-monitoring blood glucose (SMBG) methods in managing Type 2 Diabetes (T2D) in patients using basal insulin. Given the increasing prevalence of diabetes and the growing demand for innovative diabetes management solutions, successful outcomes from this study could enhance DexCom's market position against competitors like Abbott (FreeStyle Libre) and Medtronic. The study's focus on quality of life and glycemic control aligns with current healthcare trends emphasizing patient-centered care. The results may support expanded reimbursement opportunities and adoption in clinical practice, potentially leading to increased sales and market share for DexCom.